Nanotechnology Strategies To Advance Outcomes in Clinical Cancer Care

• Type of Material: Article
• Authors: Christopher M. Hartshorn, National Cancer Institute; Michelle S. Bradbury, Sloan Kettering Institute; Gregory M. Lanza, Washington University; Andre E. Nel, University of California Los Angeles; Jianghong Rao, Stanford School of Medicine; Andrew Z. Wang, University of California Los Angeles; Ulrich B. Wiesner, Cornell University; Lily Yang, Emory University; Piotr Grodzinski, National Cancer Institute
• Language: English
• Date: 2018-01-01
• Publisher: American Chemical Society
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © 2017 American Chemical Society.
• Final Published Version (URL): http://dx.doi.org/10.1021/acsnano.7b05108
• Title of Journal or Parent Work: ACS Nano
• ISSN: 1936-0851
• Volume: 12
• Issue: 1
• Start Page: 24
• End Page: 43
• Grant/Funding Information: U54-CA199081, U54-CA199075, U54-CA198999, U54-CA199092, U01-CA198913, and U01-CA198846; Portions of this work were funded by way of grants received from the National Cancer Institute.
• Keywords: METASTATIC LUNG-CANCER; radiotherapy; Physical Sciences; SOLID TUMORS; SILICA NANOPARTICLES; BREAST-CANCER; Materials Science; Chemistry, Physical; cancer; National Cancer Institute; Technology; PHOTODYNAMIC THERAPY; Science & Technology - Other Topics; DRUG-DELIVERY; Nanoscience & Nanotechnology; metastasis; Cancer Nanotechnology Plan; Chemistry, Multidisciplinary; Chemistry; nanotechnology; image-guided surgery; Materials Science, Multidisciplinary; CIRCULATING TUMOR-CELLS; oncology; biological barriers; alliance; Science & Technology; INFILTRATING LYMPHOCYTES; immunotherapy; IN-VIVO; BLOOD-BRAIN-BARRIER
• Research Categories: Health Sciences, Medicine and Surgery; Health Sciences, Oncology

Abstract

Ongoing research into the application of nanotechnology for cancer treatment and diagnosis has demonstrated its advantages within contemporary oncology as well as its intrinsic limitations. The National Cancer Institute publishes the Cancer Nanotechnology Plan every 5 years since 2005. The most recent iteration helped codify the ongoing basic and translational efforts of the field and displayed its breadth with several evolving areas. From merely a technological perspective, this field has seen tremendous growth and success. However, an incomplete understanding of human cancer biology persists relative to the application of nanoscale materials within contemporary oncology. As such, this review presents several evolving areas in cancer nanotechnology in order to identify key clinical and biological challenges that need to be addressed to improve patient outcomes. From this clinical perspective, a sampling of the nano-enabled solutions attempting to overcome barriers faced by traditional therapeutics and diagnostics in the clinical setting are discussed. Finally, a strategic outlook of the future is discussed to highlight the need for next-generation cancer nanotechnology tools designed to address critical gaps in clinical cancer care.